{
  "source": "PA-Notification-Empaveli.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1361-6\nProgram Prior Authorization/Notification\nMedication Empaveli® (pegcetacoplan)\nP&T Approval Date 7/2021, 7/2022, 8/2023, 2/2024, 4/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nEmpaveli (pegcetacoplan) is a complement inhibitor indicated for the treatment of adult\npatients with paroxysmal nocturnal hemoglobinuria (PNH).1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Empaveli will be approved based on all of the following criteria:\na. Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH)\n-AND-\nb. One of the following:\n(1) Patient will not be prescribed Empaveli in combination with another\ncomplement inhibitor used for the treatment of PNH (e.g., Bkemv, Fabhalta,\nPiaSky, Soliris, Ultomiris)\n-OR-\n(2) Patient is currently receiving another complement inhibitor (e.g., Bkemv,\nFabhalta, PiaSky, Soliris, Ultomiris) which will be discontinued and Empaveli\nwill be initiated in accordance with the United States Food and Drug\nAdministration approved labeling\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Empaveli will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Empaveli therapy\n-AND-\nb. Patient is not receiving Empaveli in combination with another complement inhibitor\nused for the treatment of PNH (e.g., Bkemv, Fabhalta, PiaSky, Soliris, Ultomiris )\n© 2025 UnitedHealthcare Services Inc.\n1\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies",
    "are may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may also be in place.\n4. References:\n1. Empaveli [package insert], Waltham, MA: Apellis Pharmaceuticals, Inc.; February 2024.\nProgram Prior Authorization/Notification - Empaveli® (pegcetacoplan)\nChange Control\n7/2021 New program\n7/2022 Annual review. Added state mandate with no other changes to coverage\ncriteria.\n8/2023 Annual review. Updated reference.\n2/2024 Added Fabhalta to list of examples of other complement inhibitors used\nfor the treatment of PNH. Revised initial authorization to 12 months.\nIncluded criteria for therapeutic duplication. Updated references.\n4/2024 Simplified criteria language for converting to new complement inhibitor\ntherapy.\n4/2025 Annual review. No changes to coverage criteria. Updated examples of\nalternate complement inhibitors.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}